<DOC>
	<DOCNO>NCT01795378</DOCNO>
	<brief_summary>The protocol treatment evaluate clinical effect donor-derived natural killer cell give HLA-mismatched hematopoietic cell transplantation .</brief_summary>
	<brief_title>Safety Efficacy Study Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation</brief_title>
	<detailed_description>Those patient acute leukemia , respond coventional chemotherapy , treat . The clinical effect evaulated term safety ( side effect ) anti-leukemia effect .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients acute leukemia , refractory standard treatment . Patients 17 year age old . The performance status patient 70 Karnofsky scale . Patients excessive hepatic dysfunction ( bilirubin le 3.0 mg/dl , AST le 5 time upper normal limit ) . Patients excessive renal dysfunction ( creatinine le 3.0 mg/dl ) . Patients clinicallyevident cardiac pulmonary dysfunction . Patients donor must sign informed consent . Patients pregnant lactate eligible .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>acute myelogenous leukemia</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>donor natural killer cell</keyword>
	<keyword>HLA-haploidentical hematopoietic cell transplantation</keyword>
</DOC>